On June 1, 2023 Landmark Bio, a collective endeavor bringing together leaders in industry, academia, and research hospitals to accelerate development and industrialization of next-generation genomic medicine, and InnDura Therapeutics ("InnDura"), a newly formed company advancing Natural Killer (NK) cell research, reported a new collaboration to develop and execute product development, regulatory, and chemistry, manufacturing and control (CMC) strategies to progress InnDura’s lead program to the clinic (Press release, InnDura Therapeutics, JUN 1, 2023, View Source [SID1234632369]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
InnDura’s technology stems from original research and related discoveries under an exclusive license from the Dana-Farber Cancer Institute and the Massachusetts Institute of Technology (MIT) that focuses on EVE16 engineering of NK cells to provide enhanced cancer cell killing with greatly reduced cellular exhaustion and fratricide. The EVE16 technology can also be applied to T cells and other forms of cell therapy. Landmark Bio will serve as InnDura’s strategic partner in the research, development and manufacturing of their pipeline products.
"Working with Landmark Bio as our strategic partner saves us the time, resources and capital of building out CMC development and manufacturing capabilities ourselves, so we can focus all our efforts on creating and advancing safer, more effective cancer treatments for patients," said John Beadle, M.D., MBA, chief executive officer (CEO) of InnDura Therapeutics. "Landmark Bio’s cell and gene therapy development, manufacturing expertise and state-of-the-art facilities are perfect for InnDura’s needs and we look forward to shaping our strategies together as our progress continues."
"We are thrilled to partner with InnDura to translate their promising research into life-saving medicines," said Ran Zheng, CEO of Landmark Bio. "This partnership is a great example of why Landmark Bio exists. In collaborating with innovators like InnDura, we can bring more advanced therapies to patients faster."